| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues [Abstract] | |||||||||
Total revenue | |||||||||
408,830 | 276,741 | 240,251 | 231,808 | 99,802 | 87,069 | 66,467 | 59,867 | 43,484 | 34,371 |
COST OF REVENUE | |||||||||
211,994 | 149,476 | 138,295 | 133,704 | 56,046 | 46,355 | 34,730 | 33,031 | 24,056 | 18,588 |
GROSS PROFIT | |||||||||
196,836 | 127,265 | 101,956 | 98,104 | 43,756 | 40,714 | 31,737 | 26,836 | 19,428 | 15,783 |
Operating expenses: | |||||||||
General and administrative | |||||||||
127,993 | 84,822 | 70,359 | 63,926 | 33,631 | 23,808 | 17,397 | 15,843 | 12,331 | 11,267 |
Research and development | |||||||||
8,487 | 3,001 | 3,636 | 4,649 | 4,198 | 2,689 | 2,440 | 2,281 | 543 | - |
Sales and marketing | |||||||||
47,350 | 29,402 | 24,001 | 23,910 | 11,562 | 11,999 | 8,726 | 7,501 | 6,963 | 7,479 |
Loss on sale of business | |||||||||
0 | 0 | -1,058 | 0 | - | - | - | - | - | - |
Impairment charges | |||||||||
- | - | - | 3,464 | - | - | - | - | - | - |
Total operating expenses | |||||||||
183,830 | 117,225 | 99,054 | 95,949 | 49,391 | 38,496 | 28,563 | 25,625 | 19,837 | 18,746 |
(LOSS) INCOME FROM OPERATIONS | |||||||||
13,006 | 10,040 | 2,902 | 2,155 | -5,635 | 2,218 | 3,174 | 1,211 | -409 | -2,963 |
Interest expense and debt termination fees, net | |||||||||
3,713 | 6,230 | 5,540 | 9,998 | 854 | 985 | 989 | - | 768 | 710 |
Other (income) expense | |||||||||
-4,630 | 14 | -12 | 0 | 2,000 | 56 | - | - | - | 370 |
Loss on extinguishment of debt | |||||||||
-1,018 | 0 | 0 | - | - | - | - | - | - | - |
INTEREST AND OTHER EXPENSE NET | |||||||||
- | - | - | - | - | - | - | -1,146 | - | -340 |
Loss before taxes | |||||||||
3,645 | 3,824 | -2,650 | -7,843 | -4,489 | 1,289 | 2,185 | 65 | -1,177 | - |
Income tax expense (benefit) | |||||||||
-4,361 | 1,184 | -2,254 | -1,701 | -1,954 | 157 | 152 | 0 | 0 | - |
NET LOSS | |||||||||
8,006 | 2,640 | -396 | -6,142 | -2,535 | 1,132 | 2,033 | 65 | -1,177 | -3,303 |
Deemed dividends on preferred stock and amortization of beneficial conversion feature | |||||||||
0 | 5,627 | 10,547 | 18,011 | 40 | - | - | - | - | - |
Amortization of preferred stock beneficial conversion feature | |||||||||
- | - | - | 6,663 | 82 | - | - | - | - | - |
Gain on redemption of preferred stock | |||||||||
0 | 9,075 | 0 | 0 | - | - | - | - | - | - |
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS | |||||||||
8,006 | 6,088 | -10,943 | -30,816 | -2,657 | 1,132 | 2,033 | - | - | - |
NET LOSS PER SHARE | |||||||||
Basic (in dollars per share) | |||||||||
0.08 | 0.07 | -0.14 | -0.40 | -0.04 | 0.02 | - | - | - | - |
Diluted (in dollars per share) | |||||||||
0.08 | 0.07 | -0.14 | -0.40 | -0.04 | 0.02 | - | - | - | - |
Basic | |||||||||
- | - | - | - | - | - | 0.04 | 0.00 | -0.03 | - |
Diluted | |||||||||
- | - | - | - | - | - | 0.04 | 0.00 | -0.03 | - |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | |||||||||
Basic (in shares) | |||||||||
100,470 | 85,618 | 79,426 | 77,542 | 60,526 | 53,483 | 48,263 | 45,027 | 42,758 | - |
Diluted (in shares) | |||||||||
103,615 | 91,568 | 79,426 | 77,542 | 60,526 | 56,016 | 52,775 | 48,715 | 42,758 | - |
NET LOSS PER SHARE - Basic and Diluted | |||||||||
- | - | - | - | - | - | - | - | - | -0.09 |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic and Diluted | |||||||||
- | - | - | - | - | - | - | - | - | 37,328 |
Clinical Services | |||||||||
Total revenue | |||||||||
361,161 | 241,873 | 213,097 | 210,159 | 98,595 | 86,408 | - | - | - | - |
Pharma Services | |||||||||
Total revenue | |||||||||
47,669 | 34,868 | 27,154 | 21,649 | 1,207 | 661 | - | - | - | - |